McLaughlin NM - Search Results

1

CD1d-based combination therapy eradicates established tumors in mice.

Teng MW, Sharkey J, McLaughlin NM, Exley MA, Smyth MJ. Teng MW, et al. Among authors: mclaughlin nm. J Immunol. 2009 Aug 1;183(3):1911-20. doi: 10.4049/jimmunol.0900796. J Immunol. 2009. PMID: 19620318 Free PMC article.

2

Endogenous IL-21 restricts CD8+ T cell expansion and is not required for tumor immunity.

Søndergaard H, Coquet JM, Uldrich AP, McLaughlin N, Godfrey DI, Sivakumar PV, Skak K, Smyth MJ. Søndergaard H, et al. J Immunol. 2009 Dec 1;183(11):7326-36. doi: 10.4049/jimmunol.0902697. Epub 2009 Nov 13. J Immunol. 2009. PMID: 19915059

3

Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion.

Teng MW, Swann JB, von Scheidt B, Sharkey J, Zerafa N, McLaughlin N, Yamaguchi T, Sakaguchi S, Darcy PK, Smyth MJ. Teng MW, et al. Cancer Res. 2010 Apr 1;70(7):2665-74. doi: 10.1158/0008-5472.CAN-09-1574. Epub 2010 Mar 23. Cancer Res. 2010. PMID: 20332236

4

DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases.

Chan CJ, Andrews DM, McLaughlin NM, Yagita H, Gilfillan S, Colonna M, Smyth MJ. Chan CJ, et al. Among authors: mclaughlin nm. J Immunol. 2010 Jan 15;184(2):902-11. doi: 10.4049/jimmunol.0903225. Epub 2009 Dec 11. J Immunol. 2010. PMID: 20008292

5

CD11c+ dendritic cells and B cells contribute to the tumoricidal activity of anti-DR5 antibody therapy in established tumors.

Haynes NM, Hawkins ED, Li M, McLaughlin NM, Hämmerling GJ, Schwendener R, Winoto A, Wensky A, Yagita H, Takeda K, Kershaw MH, Darcy PK, Smyth MJ. Haynes NM, et al. Among authors: mclaughlin nm. J Immunol. 2010 Jul 1;185(1):532-41. doi: 10.4049/jimmunol.0903624. Epub 2010 May 26. J Immunol. 2010. PMID: 20505139 Free article.

6

Toll-Like Receptor Triggering and T-Cell Costimulation Induce Potent Antitumor Immunity in Mice.

Westwood JA, Haynes NM, Sharkey J, McLaughlin N, Pegram HJ, Schwendener RA, Smyth MJ, Darcy PK, Kershaw MH. Westwood JA, et al. Among authors: mclaughlin n. Clin Cancer Res. 2009 Dec 15;15(24):7624-7633. doi: 10.1158/1078-0432.CCR-09-2201. Clin Cancer Res. 2009. PMID: 19996209 Free article.

7

Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis.

Stagg J, Divisekera U, McLaughlin N, Sharkey J, Pommey S, Denoyer D, Dwyer KM, Smyth MJ. Stagg J, et al. Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1547-52. doi: 10.1073/pnas.0908801107. Epub 2010 Jan 4. Proc Natl Acad Sci U S A. 2010. PMID: 20080644 Free PMC article.

8

IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis.

Teng MW, Andrews DM, McLaughlin N, von Scheidt B, Ngiow SF, Möller A, Hill GR, Iwakura Y, Oft M, Smyth MJ. Teng MW, et al. Proc Natl Acad Sci U S A. 2010 May 4;107(18):8328-33. doi: 10.1073/pnas.1003251107. Epub 2010 Apr 19. Proc Natl Acad Sci U S A. 2010. PMID: 20404142 Free PMC article.

9

Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth.

Teng MW, Ngiow SF, von Scheidt B, McLaughlin N, Sparwasser T, Smyth MJ. Teng MW, et al. Cancer Res. 2010 Oct 15;70(20):7800-9. doi: 10.1158/0008-5472.CAN-10-1681. Epub 2010 Oct 5. Cancer Res. 2010. PMID: 20924111

10

Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state.

Teng MW, Vesely MD, Duret H, McLaughlin N, Towne JE, Schreiber RD, Smyth MJ. Teng MW, et al. Cancer Res. 2012 Aug 15;72(16):3987-96. doi: 10.1158/0008-5472.CAN-12-1337. Epub 2012 Aug 6. Cancer Res. 2012. PMID: 22869585 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15 results

Search Page

Filters